Journal of Clinical Oncology, Vol 16, 397-404, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Survival of BRCA1 breast and ovarian cancer patients: a population- based study from southern Sweden

OT Johannsson, J Ranstam, A Borg and H Olsson
Department of Oncology, University Hospital, Lund, Sweden.

PURPOSE: Recent studies indicate that BRCA1 breast and ovarian tumors may have an advantageous survival. In this population-based study, the survival of carriers of a mutated BRCA1 gene was investigated. PATIENTS AND METHODS: The survival of 71 BRCA1-associated cancer patients (33 breast cancer, seven breast and ovarian cancer, and 31 ovarian cancer patients from 21 families with BRCA1 germline mutations) diagnosed after 1958 was compared with that of a population-based comparison group that consisted of all other invasive breast (n = 28,281) and ovarian (n = 7,011) cancers diagnosed during 1958 to 1995, as well as an age- and stage-matched control group. RESULTS: No apparent survival advantage was found for BRCA1-associated breast cancers upon direct comparison. After adjustment for age and calendar year of diagnosis, survival was equal to or worse than that of the comparison group (hazards ratio [HR], 1.5; 95% confidence interval [CI], 0.9 to 2.4). In comparison with an age- and stage-matched control group, survival again appeared equal or worse (HR, 1.5; 95% CI, 0.6 to 3.7). For BRCA1- associated ovarian cancers, an initial survival advantage was noted that disappeared with time. Due to this time dependency, multivariate analyses cannot adequately be analyzed. Compared with the age- and stage-matched control group, survival again appeared equal or worse (HR, 1.2; 95% CI, 0.5 to 2.8). CONCLUSION: The results suggest that survival for carriers of a BRCA1 mutation may be similar, or worse than, that for breast and ovarian cancer in general. This finding is in accordance with the adverse histopathologic features observed in BRCA1 tumors and underlines the need for surveillance in families that carry a BRCA1 mutation.

This article has been cited by other articles:

				D. S.P. Tan, C. Rothermundt, K. Thomas, E. Bancroft, R. Eeles, S. Shanley, A. Ardern-Jones, A. Norman, S. B. Kaye, and M. E. Gore "BRCAness" Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations J. Clin. Oncol., December 1, 2008; 26(34): 5530 - 5536. [Abstract] [Full Text] [PDF]

				D. P. Atchley, C. T. Albarracin, A. Lopez, V. Valero, C. I. Amos, A. M. Gonzalez-Angulo, G. N. Hortobagyi, and B. K. Arun Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer J. Clin. Oncol., September 10, 2008; 26(26): 4282 - 4288. [Abstract] [Full Text] [PDF]

				A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman, and S. Sadetzki Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer J. Clin. Oncol., January 1, 2008; 26(1): 20 - 25. [Abstract] [Full Text] [PDF]

				H. A. Risch, J. R. McLaughlin, D. E. C. Cole, B. Rosen, L. Bradley, I. Fan, J. Tang, S. Li, S. Zhang, P. A. Shaw, et al. Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin-Cohort Study in Ontario, Canada J Natl Cancer Inst, December 6, 2006; 98(23): 1694 - 1706. [Abstract] [Full Text] [PDF]

				C. E. Jacobi, N. J.D. Nagelkerke, J. C. van Houwelingen, and G. H. de Bock Breast Cancer Screening, Outside the Population-Screening Program, of Women from Breast Cancer Families without Proven BRCA1/BRCA2 Mutations: a Simulation Study. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 429 - 436. [Abstract] [Full Text] [PDF]

				C. T. M. Brekelmans, C. Seynaeve, M. Menke-Pluymers, H. T. Bruggenwirth, M. M. A. Tilanus-Linthorst, C. C. M. Bartels, M. Kriege, A. N. van Geel, C. M. G. Crepin, J. C. Blom, et al. Survival and prognostic factors in BRCA1-associated breast cancer Ann. Onc., March 1, 2006; 17(3): 391 - 400. [Abstract] [Full Text] [PDF]

				H. M. Sowter and A. Ashworth BRCA1 and BRCA2 as ovarian cancer susceptibility genes Carcinogenesis, October 1, 2005; 26(10): 1651 - 1656. [Abstract] [Full Text] [PDF]

				R. Hogg and M. Friedlander Biology of Epithelial Ovarian Cancer: Implications for Screening Women at High Genetic Risk J. Clin. Oncol., April 1, 2004; 22(7): 1315 - 1327. [Abstract] [Full Text] [PDF]

				S. R. Lakhani, S. Manek, F. Penault-Llorca, A. Flanagan, L. Arnout, S. Merrett, L. McGuffog, D. Steele, P. Devilee, J. G. M. Klijn, et al. Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers Clin. Cancer Res., April 1, 2004; 10(7): 2473 - 2481. [Abstract] [Full Text] [PDF]

				M. El-Tamer, D. Russo, A. Troxel, L. P. Bernardino, R. Mazziotta, A. Estabrook, B.-A. Ditkoff, F. Schnabel, and M. Mansukhani Survival and Recurrence After Breast Cancer in BRCA1/2 Mutation Carriers Ann. Surg. Oncol., February 1, 2004; 11(2): 157 - 164. [Abstract] [Full Text] [PDF]

				G. Pichert, B. Bolliger, K. Buser, and O. Pagani Evidence-based management options for women at increased breast/ovarian cancer risk Ann. Onc., January 1, 2003; 14(1): 9 - 19. [Abstract] [Full Text] [PDF]

				R. E. Buller, M. S. Shahin, J. P. Geisler, M. Zogg, B. R. De Young, and C. S. Davis Failure of BRCA1 Dysfunction to Alter Ovarian Cancer Survival Clin. Cancer Res., May 1, 2002; 8(5): 1196 - 1202. [Abstract] [Full Text] [PDF]

				M. S. van Roosmalen, L. C.G. Verhoef, P. F.M. Stalmeier, N. Hoogerbrugge, and W. A.J. van Daal Decision Analysis of Prophylactic Surgery or Screening for BRCA1 Mutation Carriers: A More Prominent Role For Oophorectomy J. Clin. Oncol., April 15, 2002; 20(8): 2092 - 2100. [Abstract] [Full Text] [PDF]

				L. Scheuer, N. Kauff, M. Robson, B. Kelly, R. Barakat, J. Satagopan, N. Ellis, M. Hensley, J. Boyd, P. Borgen, et al. Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers J. Clin. Oncol., March 1, 2002; 20(5): 1260 - 1268. [Abstract] [Full Text] [PDF]

				Y. Ben David, A. Chetrit, G. Hirsh-Yechezkel, E. Friedman, B.D. Beck, U. Beller, G. Ben-Baruch, A. Fishman, H. Levavi, F. Lubin, et al. Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors J. Clin. Oncol., January 15, 2002; 20(2): 463 - 466. [Abstract] [Full Text] [PDF]

				S. A. J. Vaziri, L. M. Krumroy, P. Elson, G. T. Budd, G. Darlington, J. Myles, R. R. Tubbs, and G. Casey Breast Tumor Immunophenotype of BRCA1-Mutation Carriers Is Influenced by Age at Diagnosis Clin. Cancer Res., July 1, 2001; 7(7): 1937 - 1945. [Abstract] [Full Text] [PDF]

				L. A. Newman, H. M. Kuerer, K. K. Hunt, G. Vlastos, F. C. Ames, M. I. Ross, and S. E. Singletary Educational Review: Role of the Surgeon in Hereditary Breast Cancer Ann. Surg. Oncol., May 1, 2001; 8(4): 368 - 378. [Abstract] [Full Text] [PDF]

				R. E. Buller, T. A. Lallas, M. S. Shahin, A. K. Sood, M. Hatterman-Zogg, B. Anderson, J. I. Sorosky, and P. A. Kirby The p53 Mutational Spectrum Associated with BRCA1 Mutant Ovarian Cancer Clin. Cancer Res., April 1, 2001; 7(4): 831 - 838. [Abstract] [Full Text]

				D. Stoppa-Lyonnet, Y. Ansquer, H. Dreyfus, C. Gautier, M. Gauthier-Villars, E. Bourstyn, K. B. Clough, H. Magdelenat, P. Pouillart, A. Vincent-Salomon, et al. Familial Invasive Breast Cancers: Worse Outcome Related to BRCA1 Mutations J. Clin. Oncol., December 15, 2000; 18(24): 4053 - 4059. [Abstract] [Full Text] [PDF]

				M. Robson Are BRCA1- and BRCA2-Associated Breast Cancers Different? Prognosis of BRCA1-Associated Breast Cancer J. Clin. Oncol., November 1, 2000; 18(90001): 113s - 118. [Abstract] [Full Text] [PDF]

				L. J. Pierce, M. Strawderman, S. A. Narod, I. Oliviotto, A. Eisen, L. Dawson, D. Gaffney, L. J. Solin, A. Nixon, J. Garber, et al. Effect of Radiotherapy After Breast-Conserving Treatment in Women With Breast Cancer and Germline BRCA1/2 Mutations J. Clin. Oncol., October 19, 2000; 18(19): 3360 - 3369. [Abstract] [Full Text] [PDF]

				V. McGuire, A. S. Whittemore, R. Norris, and I. Oakley-Girvan Survival in Epithelial Ovarian Cancer Patients with Prior Breast Cancer Am. J. Epidemiol., September 15, 2000; 152(6): 528 - 532. [Abstract] [Full Text] [PDF]

				K. H. Lu, J. E. Garber, D. W. Cramer, W. R. Welch, J. Niloff, D. Schrag, R. S. Berkowitz, and M. G. Muto Occult Ovarian Tumors in Women With BRCA1 or BRCA2 Mutations Undergoing Prophylactic Oophorectomy J. Clin. Oncol., July 14, 2000; 18(14): 2728 - 2732. [Abstract] [Full Text] [PDF]

				A. Eisen, T. R. Rebbeck, W. C. Wood, and B. L. Weber Prophylactic Surgery in Women With a Hereditary Predisposition to Breast and Ovarian Cancer J. Clin. Oncol., May 9, 2000; 18(9): 1980 - 1995. [Abstract] [Full Text] [PDF]

				J. Boyd, Y. Sonoda, M. G. Federici, F. Bogomolniy, E. Rhei, D. L. Maresco, P. E. Saigo, L. A. Almadrones, R. R. Barakat, C. L. Brown, et al. Clinicopathologic Features of BRCA-Linked and Sporadic Ovarian Cancer JAMA, May 3, 2000; 283(17): 2260 - 2265. [Abstract] [Full Text] [PDF]

				C. K. Kuhl, R. K. Schmutzler, C. C. Leutner, A. Kempe, E. Wardelmann, A. Hocke, M. Maringa, U. Pfeifer, D. Krebs, and H. H. Schild Breast MR Imaging Screening in 192 Women Proved or Suspected to Be Carriers of a Breast Cancer Susceptibility Gene: Preliminary Results Radiology, April 1, 2000; 215(1): 267 - 279. [Abstract] [Full Text]

				D. Schrag, K. M. Kuntz, J. E. Garber, and J. C. Weeks Life Expectancy Gains From Cancer Prevention Strategies for Women With Breast Cancer and BRCA1 or BRCA2 Mutations JAMA, February 2, 2000; 283(5): 617 - 624. [Abstract] [Full Text] [PDF]

				M. Robson, D. Levin, M. Federici, J. Satagopan, F. Bogolminy, A. Heerdt, P. Borgen, B. McCormick, C. Hudis, L. Norton, et al. Breast Conservation Therapy for Invasive Breast Cancer in Ashkenazi Women With BRCA Gene Founder Mutations J Natl Cancer Inst, December 15, 1999; 91(24): 2112 - 2117. [Abstract] [Full Text] [PDF]

				L. C. Verhoog, C.T.M. Brekelmans, C. Seynaeve, G. Dahmen, A. N. van Geel, C.C.M. Bartels, M.M.A. Tilanus-Linthorst, A. Wagner, P. Devilee, D.J.J. Halley, et al. Survival in Hereditary Breast Cancer Associated With Germline Mutations of BRCA2 J. Clin. Oncol., November 1, 1999; 17(11): 3396 - 3402. [Abstract] [Full Text] [PDF]

				K.-A. Phillips, I. L. Andrulis, and P. J. Goodwin Breast Carcinomas Arising in Carriers of Mutations in BRCA1 or BRCA2: Are They Prognostically Different? J. Clin. Oncol., November 1, 1999; 17(11): 3653 - 3663. [Abstract] [Full Text] [PDF]

				B. C. Turner, E. Harrold, E. Matloff, T. Smith, A. A. Gumbs, M. Beinfield, B. Ward, M. Skolnick, P. M. Glazer, A. Thomas, et al. BRCA1/BRCA2 Germline Mutations in Locally Recurrent Breast Cancer Patients After Lumpectomy and Radiation Therapy: Implications for Breast-Conserving Management in Patients With BRCA1/BRCA2 Mutations J. Clin. Oncol., October 1, 1999; 17(10): 3017 - 3024. [Abstract] [Full Text] [PDF]

				W. Burke, N. Press, and L. Pinsky BRCA1 and BRCA2: a Small Part of the Puzzle J Natl Cancer Inst, June 2, 1999; 91(11): 904 - 905. [Full Text] [PDF]

				L. Kasprzak, W. D Foulkes, and A. N Shelling Fortnightly review: Hereditary ovarian carcinoma BMJ, March 20, 1999; 318(7186): 786 - 789. [Full Text]

				K.-A. Phillips, K. Nichol, H. Ozcelik, J. Knight, S. J. Done, P. J. Goodwin, and I. L. Andrulis Frequency of p53 Mutations in Breast Carcinomas From Ashkenazi Jewish Carriers of BRCA1 Mutations J Natl Cancer Inst, March 3, 1999; 91(5): 469 - 473. [Abstract] [Full Text] [PDF]

				W. Burke and M. B. Laya Genetic Risk and Breast Cancer Survival: Another Link in the Chain of Evidence J Natl Cancer Inst, February 3, 1999; 91(3): 201 - 203. [Full Text] [PDF]

				J. S. Lee, S. Wacholder, J. P. Struewing, M. McAdams, D. Pee, L. C. Brody, M. A. Tucker, and P. Hartge Survival After Breast Cancer in Ashkenazi Jewish BRCA1 and BRCA2 Mutation Carriers J Natl Cancer Inst, February 3, 1999; 91(3): 259 - 263. [Abstract] [Full Text] [PDF]

				T. S. Frank Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist Oncologist, December 1, 1998; 3(6): 403 - 412. [Abstract] [Full Text]